Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens Authors: Dharmender Kumar, Narinder Kaur, Surender, Shahbaz Aman, Ayesha Bibi Published: 2026 ABSTRACT The unprecedented rise of antimicrobial resistance has substantially compromised the efficacy of β-lactam antibiotics, once the cornerstone of bacterial infection management, posing a major challenge to modern medicine. β-Lactams exert their antibacterial effect by inhibiting penicillin-binding proteins (PBPs) involved in cell wall synthesis; however, resistance mechanisms including porin alterations, PBP mutations, β-lactamase production, and efflux systems increasingly limit their clinical utility. In response, the development of β-lactamase inhibitors (BLIs) has become a critical strategy, with diazabicyclooctanes such as nacubactam (NAC) representing a mechanistically distinct advancement. NAC is a non-β-lactam BLI that exhibits a unique multi-modal mechanism of action encompassing inhibition of serine β-lactamases (Ambler classes A, C, and selected D), direct binding to penicillin-binding protein 2 (PBP2), and enhancement of partner β-lactam activity, including in certain β-lactamase-negative strains. Preclinical in vitro and in vivo studies demonstrate that NAC, when combined with β-lactams such as cefepime, aztreonam, or meropenem, produces substantial reductions in minimum inhibitory concentrations against multidrug-resistant Gram-negative pathogens, including carbapenemase-producing and metallo-β-lactamase (MBL)-coexpressing Enterobacterales. PBP2 targeting contributes to characteristic morphological changes and intrinsic antibacterial activity, resulting in synergistic cell wall disruption when used in combination regimens. Early clinical data from phase I studies indicate that NAC is generally well tolerated, with favorable pharmacokinetic properties and no serious safety concerns reported to date. Nevertheless, NAC lacks direct activity against class B MBLs and exhibits limited efficacy against certain non-fermenting Gram-negative organisms. Moreover, resistance mediated by β-lactamase or PBP2 alterations remains a potential concern. Importantly, robust human efficacy data from phase II and III clinical trials are currently limited. NAC represents a promising investigational BLI with a mechanistically innovative profile and broad β-lactam-potentiating capacity. While preclinical and early clinical findings support its translational potential, further clinical validation is required to define its therapeutic role, optimal combinations, and long-term impact in the management of multidrug-resistant Gram-negative infections. Introduction One of the landmark advancements in the field of medicine in 20th century was the discovery of the first commercially viable antibiotic, penicillin, by Sir Alexander Fleming. This breakthrough revolutionized the treatment of bacterial infectious diseases and saved countless lives. However, over the time the efficacy of antibiotics has been compromised due to the relentless emergence and global spread of antimicrobial resistance (AMR)[1]. Today, antibiotic resistance is a major public health challenge, rendering once-powerful treatments ineffective. Among the many antibiotic classes, β-lactams remain the most widely used in clinical settings, offering broad-spectrum coverage against both Gram-positive and Gram-negative bacteria. These antibiotics act by targeting penicillin-binding proteins (PBPs), key enzymes involved in bacterial cell wall synthesis[2]. Disruption of this pathway leads to cell lysis and death. The β-lactam class encompasses several subclasses, including penicillins, cephsalosporins, carbapenems, and monobactams. Despite their success, bacteria have evolved various mechanisms to resist β-lactam antibiotics. These include modifying porin channels in outer membranes by Gram-negative bacilli, which limits drug permeability and significantly reduces antibiotic entry. Target modification like mutations in PBPs can prevent β-lactams binding ultimately making it ineffective. For instance, altered PBPs in Staphylococcus aureus significantly reduce the binding affinity of β-lactams, leading to therapeutic failure. Enzymatic inactivation of β-lactam antibiotics by hydrolyzing the β-lactam ring regulated by β-lactamases is predominant in Gram-negative bacteria[3]. Known β-lactamases types include penicillinases, cephalosporinases, and carbapenemases which are capable of degrading multiple β-lactam subclasses. Another mechanism is Efflux systems which can expel a broad range of antibiotics, including β-lactams from bacterial cells. These pumps contribute to multidrug resistance and play roles in biofilm formation, virulence, and bacterial adaptability[4]. Despite the availability of several β-lactam/β-lactamase inhibitor (BLI) combinations, significant therapeutic gaps persist in the management of infections caused by multidrug-resistant Gram-negative pathogens. Most currently approved BLIs function solely as enzyme inhibitors and lack intrinsic antibacterial activity, rendering them ineffective against resistance mechanisms beyond β-lactamase production, such as altered PBPs or permeability defects[5]. Furthermore, emerging resistance to established BLI combinations and the limited clinical options for pathogens co-producing serine β-lactamases and metallo-β-lactamases (MBLs) underscore the urgent need for next-generation inhibitors with broader and mechanistically distinct activity[6]. Nacubactam (NAC) represents a unique advance within this context due to its dual mechanism of action, combining potent inhibition of serine β-lactamases with direct targeting of penicillin-binding protein 2 (PBP2), thereby conferring intrinsic antibacterial activity and β-lactam enhancement[7]. Although several recent reviews have addressed BLIs as a class, a focused synthesis integrating the mechanistic basis, pharmacodynamic behavior, preclinical efficacy, and translational potential of NAC is currently lacking. This review aims to fill this gap by providing a comprehensive and critical appraisal of NAC’s mode of action, spectrum of activity, resistance considerations, and clinical promise, thereby contextualizing its potential role in combating contemporary β-lactam resistance. Methodology for literature search and selection This review was conducted as a narrative, non-systematic synthesis of the available literature focusing on the mechanistic, pharmacodynamic, and therapeutic aspects of NAC and related β-lactam/BLI combinations. A comprehensive literature search was performed using multiple electronic databases, including PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, covering publications from January 2010 to May 2025. Search terms included combinations of keywords such as “nacubactam,” “OP0595,” “RG6080,” “diazabicyclooctane β-lactamase inhibitors,” “β-lactam enhancer,” “penicillin-binding protein 2,” “carbapenem-resistant Enterobacterales,” and “metallo-β-lactamase.” Boolean operators (“AND,” “OR”) were applied to refine the search strategy. Inclusion criteria comprised peer-reviewed original research articles, preclinical in vitro and in vivo studies, pharmacokinetic/pharmacodynamic analyses, clinical trial reports and relevant review articles published in English that addressed NAC’s mechanism of action, antibacterial activity, resistance profile or therapeutic potential. Exclusion criteria included non-English publications, conference abstracts without full data, non-peer-reviewed sources, and studies lacking mechanistic or translational relevance. In current review, according to the TITAN 2025 checklist for AI use disclosure, we declare that ChatGPT was used only for language refinement, while Research Rabbit and SciSpace assisted in literature search. No AI tools were involved in data analysis or interpretation[8].HIGHLIGHTSTriple action mechanism of nacubactam (NAC) including irreversible inhibition of serine β-lactamases (Ambler classes A, C, and some D), direct inhibition of penicillin-binding protein 2 (PBP2) and potentiation of β-lactam activity even in β-lactamase-negative strains. This combined mechanism enhances bacterial cell wall disruption and sets NAC apart from conventional β-lactamase inhibitors, offering a new dimension in combating multidrug-resistant pathogens.Potent synergy with β-lactams (e.g., meropenem, cefepime, aztreonam), NAC dramatically reduces minimum inhibitory concentration (MIC) values against carbapenemase-producing Enterobacterales and strains co-expressing MBLs. Preclinical studies and murine infection models show significant log-kill reductions and restoration of β-lactam efficacy in resistant strains.Broad spectrum antibacterial activity of NAC combinations specially against ESBL- & MBL/carbapenemase-producing Enterobacterales & Pseudomonas aeruginosa when paired with aztreonam.Preclinical (Phase III) and animal models confirm that NAC is safe and well tolerated, with mostly mild infusion-related adverse effects and no dose-limiting toxicities. Pharmacokinetic modeling indicates achievable bactericidal exposures with clinically realistic dosing, reinforcing its potential for translation into routine clinical therapy.Besides therapeutic promise NAC limitations include inactivity against class B metallo-β-lactamases without aztreonam, modest efficacy against some P. aeruginosa strains and potential resistance via PBP2 or β-lactamase mutations. Despite these gaps, its clinical development underscores its therapeutic promise for multidrug-resistant Gram-negative infections. HIGHLIGHTS Triple action mechanism of nacubactam (NAC) including irreversible inhibition of serine β-lactamases (Ambler classes A, C, and some D), direct inhibition of penicillin-binding protein 2 (PBP2) and potentiation of β-lactam activity even in β-lactamase-negative strains. This combined mechanism enhances bacterial cell wall disruption and sets NAC apart from conventional β-lactamase inhibitors, offering a new dimension in combating multidrug-resistant pathogens. Triple action mechanism of nacubactam (NAC) including irreversible inhibition of serine β-lactamases (Ambler classes A, C, and some D), direct inhibition of penicillin-binding protein 2 (PBP2) and potentiation of β-lactam activity even in β-lactamase-negative strains. This combined mechanism enhances bacterial cell wall disruption and sets NAC apart from conventional β-lactamase inhibitors, offering a new dimension in combating multidrug-resistant pathogens. Potent synergy with β-lactams (e.g., meropenem, cefepime, aztreonam), NAC dramatically reduces minimum inhibitory concentration (MIC) values against carbapenemase-producing Enterobacterales and strains co-expressing MBLs. Preclinical studies and murine infection models show significant log-kill reductions and restoration of β-lactam efficacy in resistant strains. Potent synergy with β-lactams (e.g., meropenem, cefepime, aztreonam), NAC dramatically reduces minimum inhibitory concentration (MIC) values against carbapenemase-producing Enterobacterales and strains co-expressing MBLs. Preclinical studies and murine infection models show significant log-kill reductions and restoration of β-lactam efficacy in resistant strains. Broad spectrum antibacterial activity of NAC combinations specially against ESBL- & MBL/carbapenemase-producing Enterobacterales & Pseudomonas aeruginosa when paired with aztreonam. Broad spectrum antibacterial activity of NAC combinations specially against ESBL- & MBL/carbapenemase-producing Enterobacterales & Pseudomonas aeruginosa when paired with aztreonam. Preclinical (Phase III) and animal models confirm that NAC is safe and well tolerated, with mostly mild infusion-related adverse effects and no dose-limiting toxicities. Pharmacokinetic modeling indicates achievable bactericidal exposures with clinically realistic dosing, reinforcing its potential for translation into routine clinical therapy. Preclinical (Phase III) and animal models confirm that NAC is safe and well tolerated, with mostly mild infusion-related adverse effects and no dose-limiting toxicities. Pharmacokinetic modeling indicates achievable bactericidal exposures with clinically realistic dosing, reinforcing its potential for translation into routine clinical therapy. Besides therapeutic promise NAC limitations include inactivity against class B metallo-β-lactamases without aztreonam, modest efficacy against some P. aeruginosa strains and potential resistance via PBP2 or β-lactamase mutations. Despite these gaps, its clinical development underscores its therapeutic promise for multidrug-resistant Gram-negative infections. Besides therapeutic promise NAC limitations include inactivity against class B metallo-β-lactamases without aztreonam, modest efficacy against some P. aeruginosa strains and potential resistance via PBP2 or β-lactamase mutations. Despite these gaps, its clinical development underscores its therapeutic promise for multidrug-resistant Gram-negative infections. Strategies to combat AMR To restore β-lactam efficacy, combination therapies with BLIs are employed. These inhibitors bind irreversibly to the active site of β-lactamases, preventing antibiotic degradation. Early examples include clavulanic acid (discovered in 1972), sulbactam (1978), and tazobactam (1984)[9]. These molecules are primarily effective against class A and some class C and D enzymes. Recent years have witnessed the development of novel BLIs with improved potency and spectrum, including diazabicyclooctanes (DBOs) avibactam, relebactam, NAC, zidebactam, and boronic acid derivatives like vaborbactam and taniborbactam. These newer agents are crucial for countering resistant pathogens, especially carbapenem-resistant Enterobacterales (CRE)[10]. Table 1 presents comparative features of DBO BLIs, Table 2 highlights the mechanistic and spectrum characteristics of clinically relevant BLIs, whereas Table 3 represents the clinical indications, safety profile, and resistance considerations of BLIs.Table 1Comparative features of diazabicyclooctane BLIs.FeatureNacubactamAvibactamZidebactamIntrinsic antibacterial activityYes (MIC 2–8 µg/ml)NoMinimalPBP2 targetingYesNoYesβ-lactam partnersMultipleLimitedCefepimeActivity vs MBL-producers (with aztreonam)StrongModerateLimitedClinical development stagePhase 3ApprovedPhase 3BLI, β-lactamase inhibitor; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; GI, gastrointestinal; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; MIC, minimum inhibitory concentration; PBP, penicillin-binding protein; VAP, ventilator-associated pneumonia. Table 2Mechanistic and spectrum characteristics of clinically relevant β-lactamase inhibitors.BLIChemical classMechanism of actionIntrinsic antibacterial activityMajor enzyme targetsClinical StatusSulbactamPenicillin sulfoneIrreversible serine acylationYes (A. baumannii)Class A, CApproved[11]Clavulanic acidClavamsIrreversible serine inhibitionNoClass AApproved[12]TazobactamPenicillin sulfoneIrreversible serine inhibitionNoClass A > CApproved[13]AvibactamDBOReversible serine inhibitionNoKPC, OXA-48, AmpCApproved[14]RelebactamDBOReversible serine inhibitionNoKPCApproved[15]ZidebactamDBOPBP2 binding + BLIMinimalKPC, AmpCPhase 3[16]NacubactamDBOPBP2 binding + BLIYesKPC, AmpC, OXA-48Phase 3[17]TaniborbactamBoronateSerine + MBL inhibitionNoKPC, NDM, VIMUnder reviewBLI, β-lactamase inhibitor; DBO, diazabicyclooctane; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; PBP, penicillin-binding protein. Table 3Clinical indications, safety profile, and resistance considerations of β-lactamase inhibitors.BLIβ-Lactam partner(s)Approved/studied indicationsCommon adverse effectsResistance mechanismsAvibactamCeftazidimecUTI, cIAI, HAP/VAPGI upset, renal effectsKPC mutationsRelebactamImipenemHAP/VAPGI upsetPorin lossZidebactamCefepimecUTI, HAP/VAPMild GIPBP alterationsNacubactamMeropenem, aztreonamcUTI, HAP/VAPHeadache, phlebitisKPC, PBP2 mutationsBLI, β-lactamase inhibitor; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; GI, gastrointestinal; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; PBP, penicillin-binding protein; VAP, ventilator-associated pneumonia. Table 1Comparative features of diazabicyclooctane BLIs.FeatureNacubactamAvibactamZidebactamIntrinsic antibacterial activityYes (MIC 2–8 µg/ml)NoMinimalPBP2 targetingYesNoYesβ-lactam partnersMultipleLimitedCefepimeActivity vs MBL-producers (with aztreonam)StrongModerateLimitedClinical development stagePhase 3ApprovedPhase 3BLI, β-lactamase inhibitor; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; GI, gastrointestinal; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; MIC, minimum inhibitory concentration; PBP, penicillin-binding protein; VAP, ventilator-associated pneumonia. Comparative features of diazabicyclooctane BLIs. BLI, β-lactamase inhibitor; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; GI, gastrointestinal; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; MIC, minimum inhibitory concentration; PBP, penicillin-binding protein; VAP, ventilator-associated pneumonia. Table 2Mechanistic and spectrum characteristics of clinically relevant β-lactamase inhibitors.BLIChemical classMechanism of actionIntrinsic antibacterial activityMajor enzyme targetsClinical StatusSulbactamPenicillin sulfoneIrreversible serine acylationYes (A. baumannii)Class A, CApproved[11]Clavulanic acidClavamsIrreversible serine inhibitionNoClass AApproved[12]TazobactamPenicillin sulfoneIrreversible serine inhibitionNoClass A > CApproved[13]AvibactamDBOReversible serine inhibitionNoKPC, OXA-48, AmpCApproved[14]RelebactamDBOReversible serine inhibitionNoKPCApproved[15]ZidebactamDBOPBP2 binding + BLIMinimalKPC, AmpCPhase 3[16]NacubactamDBOPBP2 binding + BLIYesKPC, AmpC, OXA-48Phase 3[17]TaniborbactamBoronateSerine + MBL inhibitionNoKPC, NDM, VIMUnder reviewBLI, β-lactamase inhibitor; DBO, diazabicyclooctane; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; PBP, penicillin-binding protein. Mechanistic and spectrum characteristics of clinically relevant β-lactamase inhibitors. BLI, β-lactamase inhibitor; DBO, diazabicyclooctane; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; PBP, penicillin-binding protein. Table 3Clinical indications, safety profile, and resistance considerations of β-lactamase inhibitors.BLIβ-Lactam partner(s)Approved/studied indicationsCommon adverse effectsResistance mechanismsAvibactamCeftazidimecUTI, cIAI, HAP/VAPGI upset, renal effectsKPC mutationsRelebactamImipenemHAP/VAPGI upsetPorin lossZidebactamCefepimecUTI, HAP/VAPMild GIPBP alterationsNacubactamMeropenem, aztreonamcUTI, HAP/VAPHeadache, phlebitisKPC, PBP2 mutationsBLI, β-lactamase inhibitor; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; GI, gastrointestinal; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; PBP, penicillin-binding protein; VAP, ventilator-associated pneumonia. Clinical indications, safety profile, and resistance considerations of β-lactamase inhibitors. BLI, β-lactamase inhibitor; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; GI, gastrointestinal; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; PBP, penicillin-binding protein; VAP, ventilator-associated pneumonia. NAC: a promising dual action inhibitor NAC (OP-0595, RG6080) is a BLI of the DBO class, originally discovered by Meiji Seika Pharma and Fedora Pharmaceutical[18]. Chemically, NAC features a bicyclic 1,6-diazabicyclo[3.2.1]octane core with a 7-oxo group and a sulfonate ester, giving a molecular formula of C9H16N4O7S. This structure confers resistance to β-lactamase hydrolysis and enables NAC to acylate the active-site serine of serine β-lactamases, thereby inactivating class A, C, and some class D enzymes[18,19]. Notably, NAC also exhibits intrinsic antibacterial activity by binding PBP2 and acts as a “β-lactam enhancer” that boosts the efficacy of partner β-lactam antibiotics – a unique triple-action profile first described in 2015[18]. NAC shows broad-spectrum activity in combination with other β-lactam partners against challenging Gram-negative pathogens. It effectively inhibits class A β-lactamases [including ESBLs and Klebsiella pneumoniae carbapenemase (KPCs)], class C cephalosporinases (AmpC), and certain class D carbapenemases (e.g., OXA-48), thereby restoring the potency of β-lactams against these resistant Enterobacterales[6,19]. Although NAC alone has only modest antibacterial potency (MIC90 2–8 mg/L against Enterobacterales), co-administration with a β-lactam dramatically reduces the required antibiotic concentration. For instance, aztreonam/NAC and cefepime/NAC showed greatly lowered MIC values against MBL-producing Enterobacterales (IMP-type) and ESBL-producing strains compared to the β-lactams alone[19]. NAC’s PBP2-targeting effect also contributes to synergy: it can enhance partner drug activity even against some β-lactamase-negative mutants (via a β-lactamase-independent mechanism)[18]. This inhibitor’s efficacy has been demonstrated in multiple preclinical infection models. In neutropenic mouse lung and urinary tract infection studies, the combination of meropenem plus NAC produced significantly greater bacterial clearance against carbapenem-resistant Enterobacteriaceae (including KPC-producing & MDR strains) compared to either agent alone[20,21]. Similarly, meropenem–NAC was highly efficacious against difficult-to-treat Pseudomonas aeruginosa harboring AmpC or KPC β-lactamases in an animal pneumonia model. These findings highlight NAC’s ability to broaden the spectrum and enhance the potency of existing β-lactams against otherwise resistant pathogens[22–24]. Meropenem/NAC and cefepime/NAC combinations have now progressed into clinical trials for complicated urinary tract infections and other serious bacterial infections. Phase 1 studies showed that NAC is well tolerated when given with meropenem, with mostly mild infusion-related side effects observed (e.g., phlebitis and headache)[6]. By overcoming key resistance mechanisms, NAC-based regimens offer a promising new option for treating MDR Gram-negative infections, including those caused by carbapenemase-producing Enterobacterales. The clinical promise of NAC is underscored by its broad spectrum when paired appropriately and its unique multi-modal mechanism of action, which together may extend the utility of existing β-lactams against emerging resistant pathogens[22,24–27]. Mechanistic basis of NAC activity Inhibition of serine β-lactamases NAC (formerly RG6080 or OP0595) is a bridged DBO non-β-lactam BLI that exerts potent activity against serine β-lactamases. It irreversibly inhibits Ambler class A enzymes, including KPC, TEM, and CTX-M β-lactamases, as well as class C cephalosporinases (AmpC) and selected class D enzymes such as OXA-48[28]. Unlike clavulanic acid and other early BLIs, NAC lacks a β-lactam core and instead utilizes its DBO scaffold to covalently acylate the active-site serine residue, rendering the enzyme catalytically inactive and protecting partner β-lactam antibiotics from hydrolysis[29]. Biochemical studies demonstrate rapid acylation of KPC-2 carbapenemase by NAC, although certain KPC variants, such as K234R, exhibit reduced susceptibility, highlighting potential resistance pathways[30]. Structural analyses reveal formation of a stable covalent NAC–enzyme adduct with retention of the sulfate moiety, consistent with irreversible inhibition[7]. Importantly, NAC does not inhibit class B MBLs, necessitating combination strategies most notably with aztreonam for effective activity against MBL-producing pathogens[31]. PBP2 targeting In addition to β-lactamase inhibition, NAC directly binds and inhibits PBP2, a key enzyme involved in bacterial cell wall elongation. Structurally, NAC is related to avibactam but incorporates an ethanolamine moiety that introduces a positively charged primary amine at physiological pH, enhancing its affinity for PBP2[23]. On electrophoretic analysis, it has been observed that NAC has high affinity for PBP2, resulting in disruption of peptidoglycan biosynthesis, compromising bacterial cell wall integrity and contributing directly to antibacterial activity. It has also been observed that other conventional BLIs lack this property. This feature distinguishes NAC from avibactam and relebactam as they inhibit β-lactamases without PBP engagement. Experimental evidence supporting PBP2 targeting includes binding assays in which membrane preparations containing PBPs from Escherichia coli were incubated with NAC and subsequently exposed to Bocillin FL, a fluorescent penicillin analog[32]. Intrinsic antibacterial and β-lactam enhancer activity As a functional consequence of PBP2 inhibition, NAC exhibits measurable intrinsic antibacterial activity, a property that is unusual among BLIs. In vitro studies have shown that NAC alone demonstrates MIC values typically ranging from 2 to 8 µg/ml against Enterobacterales, including K. pneumoniae and E. coli producing CTX-M and KPC enzymes. Time-kill assays further indicate that NAC monotherapy can achieve >1-log reductions in bacterial counts in susceptible strains, reflecting moderate bacteriostatic to bactericidal activity[7,23,24,29]. Although insufficient for standalone therapy, this intrinsic activity is mechanistically and clinically significant. Quantitatively, this distinguishes NAC from avibactam and relebactam, which exhibit MICs exceeding 64 µg/ml and are considered microbiologically inactive when tested alone. Zidebactam displays limited intrinsic activity but relies predominantly on cooperative PBP2–PBP3 inhibition in combination with cefepime rather than independent antibacterial effects. In comparative in vitro studies, NAC-based combinations have been shown to reduce β-lactam MICs by approximately 8- to 128-fold – an effect consistently greater than that observed with avibactam in similar resistance backgrounds, particularly among isolates co-producing serine β-lactamases and MBLs[33–35]. This dual mechanism enables NAC to function not merely as a BLI but as a β-lactam enhancer, potentiating the activity of partner β-lactams even in β-lactamase-negative or permeability-compromised strains. The intrinsic antibacterial effect appears largely confined to Enterobacterales, as Gram-positive organisms and non-fermenters such as P. aeruginosa and Acinetobacter baumannii show minimal susceptibility to NAC alone, although they may respond favorably to NAC-based combinations due to restored β-lactam efficacy[36,37]. Collectively, these properties confer NAC a broader and mechanistically distinct antibacterial profile compared with earlier and contemporary BLIs. Morphological effects The inhibition of PBP2 by NAC leads to notable morphological changes in treated bacterial cells. PBP2 is essential for maintaining rod shape in Gram-negative bacilli. Its inhibition disrupts cell elongation, resulting in rounding or spherical morphotypes, which are typically nonviable. These changes have been observed microscopically in several studies involving both fixed and live bacterial imaging[7]. In a study conducted by Morinaka et al, thin layers of Mueller-Hinton agar containing NAC were inoculated with E. coli suspensions and examined under phase-contrast microscopy. Bacteria exposed to NAC lost their rod-like shape and became spherical, a morphological hallmark of PBP2 inhibition[26]. These findings were corroborated using electron microscopy by Livermore et al, who observed disrupted cell wall integrity and cytoplasmic leakage in treated cells[38]. The morphological effects become more pronounced when NAC is combined with β-lactams that target other PBPs. For instance, cefepime targets PBP3, and when used in conjunction with NAC, a dual inhibition occurs that overwhelms the bacterial cell wall biosynthetic machinery. This combined effect results in gross morphological abnormalities, membrane rupture, and eventual lysis[18]. Further confirmation of PBP2-targeted disruption was obtained using fluorescent penicillin-binding assays. These assays showed diminished fluorescence at the PBP2 band in SDS-PAGE gels after exposure to NAC, indicating occupancy and inactivation of PBP2 binding sites[39]. In time-lapse microscopy studies, cell swelling, bulging, and blebbing preceded cell death, with characteristic cytoplasmic extrusion seen in late stages of exposure[40]. Activity of NAC with β-lactams against MBLs NAC (OP0595) is a DBO BLI that inhibits class A and C enzymes and also binds PBP2, giving it intrinsic “β-lactam enhancer” activity[23]. Importantly, NAC does not inhibit MBLs, but by protecting a co-administered β-lactam from serine β-lactamases and targeting PBP2, it can overcome MBL-producer resistance[23,17]. For example, Mushtaq et al found that meropenem + NAC and cefepime + NAC inhibited 80–93% of NDM/VIM-producing Enterobacteriaceae (vs none for meropenem or cefepime alone)[24]. Moreover, aztreonam + NAC “almost universally active” against MBL producers: unlike aztreonam/avibactam, the NAC combination achieved an MIC_90 of 0.5–1 mg/L by also leveraging the PBP2 effect[24,17]. In short, although MBLs degrade most β-lactams, adding NAC can restore β-lactam activity via dual β-lactamase inhibition (of co-produced serine enzymes) and synergistic PBP targeting[23,17]. Known published β-lactam–NAC combinations include meropenem + NAC[23], cefepime + NAC[24], aztreonam + NAC[24], piperacillin + NAC[17], and imipenem + NAC[17]. All these combos dramatically lowered MICs against resistant strains. For instance, Le Terrier et al showed aztreonam + NAC was active against ~ 84% of diverse NDM/VIM Enterobacterales (higher than aztreonam + avibactam at 70%)[26]. Livermore et al similarly noted that NAC combinations had broad activity against Enterobacteriaceae with ESBLs/AmpCs/MBLs[17]. Antibacterial activity of NAC with other antibiotics against carbapenemase-producers Beyond MBLs, NAC combinations markedly improve activity against organisms producing serine carbapenemases (e.g., KPC, OXA-48) and AmpC enzymes. For KPC-producing K. pneumoniae, Barnes et al showed that meropenem + NAC restored susceptibility in isolates carrying bla_KPC-2/3[23]. In global surveillance, Harding et al found meropenem/NAC (1:1) was active against 99% of Enterobacterales, including many carbapenemase producers and even some ceftazidime/avibactam-resistant isolates[41]. In animal models, humanized dosing of meropenem + NAC led to significant bacterial clearance: a neutropenic mouse lung model showed 1.5log10 reduction in lung CFU against class A carbapenemase (KPC or IMI) producers, whereas monotherapy had little effect[20]. Other β-lactam partners with NAC have shown similar synergy. In a murine thigh infection study, Hagihara et al tested meropenem, cefepime, or aztreonam each combined with NAC against CRE with various carbapenemases (IMP, KPC, OXA-48)[42]. All three NAC-containing regimens produced greater log kills than monotherapies, suggesting efficacy against multiple carbapenemase genotypes[42]. Notably, Monogue et al reported that in a complicated UTI model, meropenem/NAC (humanized exposures) achieved ≥3log10 kill in 9/10 isolates spanning NDM, KPC, OXA, and ESBL enzymes, whereas either drug alone achieved ≤1-log kill[21]. Meropenem/NAC was even more active than ceftazidime/avibactam against some resistant strains, yielding up to a 6log10 CFU reduction[21]. Similarly, Asempa et al showed meropenem/NAC produced ≥2.7-log kill against AmpC-overproducing and KPC-positive P. aeruginosa (far exceeding meropenem alone)[22]. Safety and tolerability of NAC combinations Phase I studies in healthy adults have shown that intravenous NAC (alone or with meropenem) is generally safe and well tolerated. Most adverse events were mild infusion-site reactions or headaches, resolving without sequelae. Importantly, no dose-limiting toxicities or serious drug-related AEs occurred at doses up to 2 g every 8 h. Co-administration with meropenem did not significantly alter the pharmacokinetics of NAC (nor vice versa). Exploratory renal biomarkers remained within normal limits even at high doses, and no QT prolongation was observed. NAC plus meropenem showed no unexpected toxicities: linear PK (half-life 1.5 h, 60% renally excreted) and a favorable safety profile support advancing this combination in clinical development[7]. Broader antibacterial activity NAC significantly broadens the spectrum of its partner β-lactams against resistant Gram-negatives. Table 4 shows the restoration of β-lactam activity by NAC combinations against multidrug-resistant Gram-negative pathogens harboring diverse resistance. In vitro and animal studies show: Enterobacterales: In combination, meropenem–NAC and cefepime–NAC are active against K. pneumoniae and E. coli producing ESBLs, AmpCs, KPCs, or OXA-48. When paired with aztreonam, NAC also protects against NDM and other metallo-carbapenemase producers. Notably, aztreonam/NAC has demonstrated potent in vivo activity against NDM-producing K. pneumoniae[43].P. aeruginosa: Although most studies focus on Enterobacterales, murine pneumonia models reveal that meropenem–NAC kills AmpC-overproducing and KPC-expressing P. aeruginosa. In one study, the combination achieved 3–4log10 CFU lung reductions relative to meropenem alone[22]. This suggests NAC can overcome some P. aeruginosa resistance when paired with an effective β-lactam.Mycobacteria: Unusually, NAC also potentiates the activity of β-lactams against Mycobacterium abscessus. In vitro, adding 8 μg/ml NAC to meropenem reduced M. abscessus MICs by ~ 8-fold, and adding 8 μg/ml to cefepime reduced MICs 2-fold. This enhancement parallels that seen with avibactam/relebactam, indicating DBOs can inhibit mycobacterial β-lactamases.In vivo efficacy: NAC combinations work in animal infection models. For example, cefepime–NAC cured murine pneumonia and thigh infections caused by CTX-M-15 E. coli, KPC-2 K. pneumoniae, or AmpC-derepressed P. aeruginosa. Likewise, meropenem–NAC achieved bacterial stasis or kill in Enterobacteriaceae cUTI models.Table 4Restoration of β-lactam activity by nacubactam combinations against multidrug-resistant Gram-negative pathogens harboring diverse resistance.DRUG (inhibitor)Bacterial strainsActivity againstCombination with β-lactamMIC of Nacubactam aloneMIC of β-Lactam aloneMIC of Nacubactam with β-LactamRef.Nacubactam/OP0595Klebsiella pneumoniaeNDM-1Aztreonam + nacubactamCefepime + nacubactam--2 mg/L-[35]IMP-60.25 mg/L-OXA-481 mg/L2 mg/LKPC-21 mg/L1 mg/LEscherichia coliCTX-M-15Aztreonam + nacubactamCefepime + nacubactam--1 mg/L1 mg/LNacubactam/OP0595K. pneumoniaeKPC-2Nacubactam + meropenem1 mg/L16 mg/L0.25 mg/LKPC-38 mg/LE. coliKPC-2Nacubactam + meropenem1 mg/L1 mg/L0.12 mg/L[23,21]KPC-32 mg/L0.05 mg/L0.06 mg/LKPC-42 mg/L0.25 mg/L0.12 mg/LKPC-52 mg/L0.12 mg/L0.06 mg/L2 mg/L0.25 mg/L0.06 mg/LKPC-62 mg/L0.25 mg/L0.06 mg/L2 mg/L0.5 mg/L0.12 mg/LKPC-7KPC-8Nacubactam/OP0595Citrobacter spp.NDMAztreonam + nacubactamCefepime + NacubactamMeropenem+Nacubactam32 mg/L-0.03 mg/L0.03 mg/L0.03 mg/L[24]Enterobacter spp.2 mg/L2 mg/L0.03 mg/L0.03 mg/L0.03 mg/L0.03 mg/L0.03 mg/L0.03 mg/LE. coli.32 mg/L32 mg/L0.03 mg/L0.03 mg/L0.03 mg/LKlebsiella spp.0.03 mg/L1 mg/L1 mg/LVIMProteeaeNacubactam/OP0595E. coli.-Meropenem + nacubactamCeftazidime + Avibactam2 mg/L0.003 mg/L0.004 mg/L0.12 mg/L[21]0.6 mg/LKlebsiella spp.32 mg/L0.003 mg/L0.004 mg/L0.12 mg/L0.004 mg/L0.25 mg/L0.25 mg/L0.004 mg/L0.12 mg/LSerratia marcescens32 mg/L0.006 mg/L0.004 mg/L2 mg/L16 mg/L4 mg/L0.003 mg/L32 mg/L0.003 mg/L0.25 mg/lEnterobacter cloacae32 mg/L0.5 mg/LCitrobacter freundii Pseudomonas spp.32 mg/L32 mg/L32 mg/LAcinetobacter spp.Nacubactam/OP0595K. pneumoniaeNDMMeropenem + nacubactamCeftazidime + Avibactam256 mg/L64 mg/L4 mg/L64 mg/L[21]KPC2 mg/L64 mg/L1 mg/L256 mg/LE. coliOXA256 mg/L1 mg/L64 mg/LCTX-M256 mg/LE. cloacaeSHVTEMNacubactam/OP0595E. coliCTX-M-15Cefepime + nacubactam2 ug/ml64 ug/ml0.004 ug/ml[18]2 ug/ml64 ug/ml0.004 ug/mlOXA-1K. pneumoniaeKPC-22 ug/ml64 ug/ml0.004 ug/mlKPC-34 ug/ml64 ug/ml0.004 ug/mlNacubactam/OP0595E. coliKPCPiperacillin + nacubactam32 ug/ml1 ug/ml0.12 ug/ml[17]K. pneumoniaeNDMCefepime + nacubactam1 ug/ml0.016 ug/mlVIMAztreonam + nacubactam1 ug/ml0.016 ug/mlOXA-48Citrobacter spp.Meropenem + nacubactam1 ug/ml0.016 ug/mlEnterobacter spp.KPC, Klebsiella pneumoniae carbapenemase; MIC, minimum inhibitory concentration; PBP, penicillin-binding protein. Enterobacterales: In combination, meropenem–NAC and cefepime–NAC are active against K. pneumoniae and E. coli producing ESBLs, AmpCs, KPCs, or OXA-48. When paired with aztreonam, NAC also protects against NDM and other metallo-carbapenemase producers. Notably, aztreonam/NAC has demonstrated potent in vivo activity against NDM-producing K. pneumoniae[43]. Enterobacterales: In combination, meropenem–NAC and cefepime–NAC are active against K. pneumoniae and E. coli producing ESBLs, AmpCs, KPCs, or OXA-48. When paired with aztreonam, NAC also protects against NDM and other metallo-carbapenemase producers. Notably, aztreonam/NAC has demonstrated potent in vivo activity against NDM-producing K. pneumoniae[43]. P. aeruginosa: Although most studies focus on Enterobacterales, murine pneumonia models reveal that meropenem–NAC kills AmpC-overproducing and KPC-expressing P. aeruginosa. In one study, the combination achieved 3–4log10 CFU lung reductions relative to meropenem alone[22]. This suggests NAC can overcome some P. aeruginosa resistance when paired with an effective β-lactam. P. aeruginosa: Although most studies focus on Enterobacterales, murine pneumonia models reveal that meropenem–NAC kills AmpC-overproducing and KPC-expressing P. aeruginosa. In one study, the combination achieved 3–4log10 CFU lung reductions relative to meropenem alone[22]. This suggests NAC can overcome some P. aeruginosa resistance when paired with an effective β-lactam. Mycobacteria: Unusually, NAC also potentiates the activity of β-lactams against Mycobacterium abscessus. In vitro, adding 8 μg/ml NAC to meropenem reduced M. abscessus MICs by ~ 8-fold, and adding 8 μg/ml to cefepime reduced MICs 2-fold. This enhancement parallels that seen with avibactam/relebactam, indicating DBOs can inhibit mycobacterial β-lactamases. Mycobacteria: Unusually, NAC also potentiates the activity of β-lactams against Mycobacterium abscessus. In vitro, adding 8 μg/ml NAC to meropenem reduced M. abscessus MICs by ~ 8-fold, and adding 8 μg/ml to cefepime reduced MICs 2-fold. This enhancement parallels that seen with avibactam/relebactam, indicating DBOs can inhibit mycobacterial β-lactamases. In vivo efficacy: NAC combinations work in animal infection models. For example, cefepime–NAC cured murine pneumonia and thigh infections caused by CTX-M-15 E. coli, KPC-2 K. pneumoniae, or AmpC-derepressed P. aeruginosa. Likewise, meropenem–NAC achieved bacterial stasis or kill in Enterobacteriaceae cUTI models. In vivo efficacy: NAC combinations work in animal infection models. For example, cefepime–NAC cured murine pneumonia and thigh infections caused by CTX-M-15 E. coli, KPC-2 K. pneumoniae, or AmpC-derepressed P. aeruginosa. Likewise, meropenem–NAC achieved bacterial stasis or kill in Enterobacteriaceae cUTI models. Table 4Restoration of β-lactam activity by nacubactam combinations against multidrug-resistant Gram-negative pathogens harboring diverse resistance.DRUG (inhibitor)Bacterial strainsActivity againstCombination with β-lactamMIC of Nacubactam aloneMIC of β-Lactam aloneMIC of Nacubactam with β-LactamRef.Nacubactam/OP0595Klebsiella pneumoniaeNDM-1Aztreonam + nacubactamCefepime + nacubactam--2 mg/L-[35]IMP-60.25 mg/L-OXA-481 mg/L2 mg/LKPC-21 mg/L1 mg/LEscherichia coliCTX-M-15Aztreonam + nacubactamCefepime + nacubactam--1 mg/L1 mg/LNacubactam/OP0595K. pneumoniaeKPC-2Nacubactam + meropenem1 mg/L16 mg/L0.25 mg/LKPC-38 mg/LE. coliKPC-2Nacubactam + meropenem1 mg/L1 mg/L0.12 mg/L[23,21]KPC-32 mg/L0.05 mg/L0.06 mg/LKPC-42 mg/L0.25 mg/L0.12 mg/LKPC-52 mg/L0.12 mg/L0.06 mg/L2 mg/L0.25 mg/L0.06 mg/LKPC-62 mg/L0.25 mg/L0.06 mg/L2 mg/L0.5 mg/L0.12 mg/LKPC-7KPC-8Nacubactam/OP0595Citrobacter spp.NDMAztreonam + nacubactamCefepime + NacubactamMeropenem+Nacubactam32 mg/L-0.03 mg/L0.03 mg/L0.03 mg/L[24]Enterobacter spp.2 mg/L2 mg/L0.03 mg/L0.03 mg/L0.03 mg/L0.03 mg/L0.03 mg/L0.03 mg/LE. coli.32 mg/L32 mg/L0.03 mg/L0.03 mg/L0.03 mg/LKlebsiella spp.0.03 mg/L1 mg/L1 mg/LVIMProteeaeNacubactam/OP0595E. coli.-Meropenem + nacubactamCeftazidime + Avibactam2 mg/L0.003 mg/L0.004 mg/L0.12 mg/L[21]0.6 mg/LKlebsiella spp.32 mg/L0.003 mg/L0.004 mg/L0.12 mg/L0.004 mg/L0.25 mg/L0.25 mg/L0.004 mg/L0.12 mg/LSerratia marcescens32 mg/L0.006 mg/L0.004 mg/L2 mg/L16 mg/L4 mg/L0.003 mg/L32 mg/L0.003 mg/L0.25 mg/lEnterobacter cloacae32 mg/L0.5 mg/LCitrobacter freundii Pseudomonas spp.32 mg/L32 mg/L32 mg/LAcinetobacter spp.Nacubactam/OP0595K. pneumoniaeNDMMeropenem + nacubactamCeftazidime + Avibactam256 mg/L64 mg/L4 mg/L64 mg/L[21]KPC2 mg/L64 mg/L1 mg/L256 mg/LE. coliOXA256 mg/L1 mg/L64 mg/LCTX-M256 mg/LE. cloacaeSHVTEMNacubactam/OP0595E. coliCTX-M-15Cefepime + nacubactam2 ug/ml64 ug/ml0.004 ug/ml[18]2 ug/ml64 ug/ml0.004 ug/mlOXA-1K. pneumoniaeKPC-22 ug/ml64 ug/ml0.004 ug/mlKPC-34 ug/ml64 ug/ml0.004 ug/mlNacubactam/OP0595E. coliKPCPiperacillin + nacubactam32 ug/ml1 ug/ml0.12 ug/ml[17]K. pneumoniaeNDMCefepime + nacubactam1 ug/ml0.016 ug/mlVIMAztreonam + nacubactam1 ug/ml0.016 ug/mlOXA-48Citrobacter spp.Meropenem + nacubactam1 ug/ml0.016 ug/mlEnterobacter spp.KPC, Klebsiella pneumoniae carbapenemase; MIC, minimum inhibitory concentration; PBP, penicillin-binding protein. Restoration of β-lactam activity by nacubactam combinations against multidrug-resistant Gram-negative pathogens harboring diverse resistance. KPC, Klebsiella pneumoniae carbapenemase; MIC, minimum inhibitory concentration; PBP, penicillin-binding protein. NAC extends β-lactam coverage to organisms producing ESBLs, AmpCs, KPCs, OXA-48, and even co-expressed MBLs[43]. Its PBP2 activity also explains why cefepime–NAC shows unexpected activity against some MBL-producing Enterobacterales. Pharmacodynamic modeling and efficacy of NAC combinations Pharmacokinetic/pharmacodynamic analyses confirm that NAC markedly enhances β-lactam efficacy. In vivo models demonstrate that NAC-containing regimens achieve bacterial kill correlated with drug exposure. For example, in a mouse pneumonia model, combinations of aztreonam, cefepime, or meropenem with NAC produced significantly greater log-kill against CRE than monotherapy[44]. Hagihara et al found that the percentage of free drug time above MIC (%fT>MIC) in epithelial lining fluid (ELF) correlated strongly with bacterial kill: R2 was 0.88 for aztreonam/NAC and 0.75 for cefepime/NAC[44]. These data allowed sigmoid E_max modeling of NAC combos. In a PK/PD modeling study, Igarashi et al introduced an instantaneous-MIC (MICi) method and determined target exposures for NAC combinations[43]. They estimated that for aztreonam/NAC, 38% fT>MIC is needed for 1-log10 kill and 75% for 2-log10 kill in murine lung infection[43]. Using human PK simulations, the authors predicted that clinically realistic dosing (aztreonam 0.5 g + NAC 0.5 g q8h) would achieve the 2-log kill target 100% of the time for pathogens with MIC≤1 mg/L[45]. In other words, bactericidal exposure levels are attainable with approved or investigational dosing. These PK/PD findings align with the empirical efficacy seen in infection models. In the murine UTI study, the meropenem/NAC human-equivalent regimen gave ≥3log reductions against carbapenemase-producers[21]. In the pneumonia model, aztreonam/NAC or cefepime/NAC with %fT>MIC in ELF above 60–70% consistently produced >3log10 kill[44]. Thus, both modeling and animal data indicate that NAC co-administration greatly increases the %fT>MIC of partner β-lactams, enabling high-level bacterial eradication at achievable doses[45]. NAC has been studied with meropenem[20,23], aztreonam[21,24], cefepime[24,44], and piperacillin and imipenem/biapenem[17]. Each of these β-lactam + NAC regimens significantly extended spectrum against CRE or MBL-producers. No peer-reviewed studies have yet tested NAC with non-β-lactam agents (e.g., polymyxins, aminoglycosides), so evidence for such combinations is lacking. Limitations Despite its promise, NAC has important limitations. Chiefly, it lacks activity against MBLs on its own, so it must be paired with aztreonam (a monobactam not hydrolyzed by MBLs) to treat NDM/VIM producers[43]. NAC’s efficacy in P. aeruginosa is also limited – for example, cefepime–NAC has shown no improvement over cefepime alone against P. aeruginosa in some studies. This likely reflects P. aeruginosa’s unique PBP profile and reduced penetration. Resistance can emerge via target mutations. Specific substitutions in KPC-2 (e.g., S130G, K234R) substantially raise NAC K_i and increase MICs. Similarly, mutations in the PBP2 target (identified in a clinical K. pneumoniae isolate) elevated the NAC MIC >256 μg/m.. Thus, both enzyme variation and PBP alterations can undermine NAC. In practice, NAC monotherapy is ineffective: in vitro it shows weak killing and in animal models (e.g., mouse lung), NAC or meropenem alone failed to reduce bacterial burden, whereas the combination succeeded[22]. Other drawbacks include its pharmacology and developmental status. NAC is only available as an intravenous agent and is excreted largely unchanged by the kidneys (dose adjustment needed in renal impairment). It has been well tolerated in phase I studies, but no large-scale clinical trials have yet confirmed its efficacy. Finally, some Gram-negatives remain refractory: notably, Acinetobacter baumannii’s chromosomal AmpC is poorly inhibited by all new BLIs[46], so NAC provides no activity against A. baumannii. In summary, while NAC greatly augments β-lactam therapy against many resistant Enterobacterales, its spectrum has gaps (MBLs, certain non-fermenters), and resistance via β-lactamase or PBP mutations must be monitored. Clinical relevance and translational positioning of NAC-based combinations From a clinical standpoint, NAC -based regimens occupy a distinct and potentially complementary position within the expanding armamentarium of β-lactam/BLI combinations[28]. Compared with meropenem/vaborbactam, which demonstrates excellent activity against KPC-producing Enterobacterales but limited efficacy against non-KPC carbapenemase, NAC offers broader mechanistic versatility[47]. While vaborbactam functions exclusively as a KPC inhibitor without intrinsic antibacterial activity, NAC enhances β-lactam efficacy across multiple resistance backgrounds through combined serine β-lactamase inhibition and PBP2 targeting. This distinction is particularly relevant in clinical settings where carbapenem resistance is multifactorial, involving enzyme production alongside permeability defects or altered PBPs[37]. Cefepime–zidebactam represents another advanced β-lactam/BLI combination with strong translational promise. Although zidebactam shares PBP2 binding as a mechanistic feature, its antibacterial contribution is largely dependent on cooperative inhibition with cefepime and is therefore constrained to a fixed partner[48]. In contrast, NAC has demonstrated β-lactam-enhancing activity with multiple agents, including meropenem, cefepime, and aztreonam. This partner flexibility may translate into broader clinical applicability, enabling therapy to be tailored according to pathogen susceptibility, infection site, and patient-specific considerations. A particularly important translational advantage of NAC lies in its activity against MBL-producing Enterobacterales when combined with aztreonam[24]. Unlike meropenem–vaborbactam and cefepime–zidebactam, which lack reliable activity against MBL producers, aztreonam–NAC restores antibacterial activity by protecting the monobactam from co-produced serine β-lactamases while simultaneously impairing cell wall synthesis. This positions NAC-based regimens as attractive therapeutic options in regions with a high prevalence of NDM- or VIM-producing pathogens, where treatment choices remain extremely limited[17,49,50]. From a resistance perspective, NAC addresses several contemporary mechanisms encountered in CRE through inhibition of class A, class C, and selected class D β-lactamases. However, resistance emergence remains a concern. Mutations in β-lactamases, particularly certain KPC variants, as well as alterations in the PBP2 target, have been shown to reduce NAC activity[51,52]. These observations highlight the need for continued resistance surveillance and rational clinical deployment to preserve therapeutic utility. Despite encouraging preclinical and early clinical data, important gaps in evidence remain. Most available efficacy data are derived from in vitro studies and animal infection models, with limited large-scale clinical outcome data. Further clinical trials are needed to define optimal partner β-lactams, dosing strategies, and patient populations most likely to benefit. In addition, inconsistent activity against non-fermenting Gram-negative pathogens and the absence of direct MBL inhibition necessitate careful combination selection. Real-world studies evaluating resistance evolution, safety in special populations, and comparative effectiveness against other next-generation β-lactam/BLI combinations will be critical for guiding antimicrobial stewardship. NAC occupies a unique position among emerging BLIs due to its multi-modal mechanism, partner flexibility, and capacity to potentiate β-lactams against diverse resistance phenotypes. While these attributes offer clear translational advantages, their clinical impact will ultimately depend on appropriate combination strategies, resistance monitoring, and robust clinical validation. Conclusion NAC represents a mechanistically innovative addition to the evolving class of BLIs, distinguished by its combined inhibition of serine β-lactamases and direct targeting of PBP2. This dual mode of action confers intrinsic antibacterial activity and enables substantial potentiation of multiple β-lactam partners across diverse resistance mechanisms, including CRE. Preclinical studies and pharmacokinetic/pharmacodynamic modeling consistently demonstrate enhanced antibacterial efficacy when NAC is used in combination with appropriate β-lactams, supporting its translational potential. However, it is important to recognize that the current evidence base for NAC is largely derived from in vitro investigations, animal infection models, and phase I clinical studies assessing safety and pharmacokinetics. Robust human efficacy data from phase II and phase III clinical trials are currently limited, and the clinical performance of NAC-based regimens across different infection syndromes and patient populations remains to be fully established. Furthermore, the potential for resistance emergence through β-lactamase or PBP alterations underscores the need for ongoing surveillance and judicious clinical use. In this context, NAC should be viewed as a promising but still investigational agent whose ultimate clinical role will depend on forthcoming clinical trial outcomes, comparative effectiveness studies, and real-world experience. Continued evaluation through well-designed clinical studies and antimicrobial stewardship frameworks will be essential to determine whether the mechanistic advantages observed preclinically translate into consistent and durable clinical benefit in the management of multidrug-resistant Gram-negative infections.